[ Ссылка ]

Effective treatment of acute-on-chronic liver failure (#ACLF) is an urgent and unmet need. The A-TANGO consortium tests and evaluates an innovative new treatment that aims to reduce inflammation and improve hepatocyte proliferation by repurposing TAK-242, an antagonist of toll-like receptor 4, in combination with G-CSF (granulocyte colony-stimulating factor). We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

In the project's first Masterclass, Prof. Dr. Thomas Berg, Head of Hepatology Department at the University of Leipzig (ULEI) and currently Secretary General of the European Association for the Study of the Liver (EASL), provides an in-depth overview of promising research advances and novel treatment strategies for patients suffering from #cirrhosis, #decompensation, and acute-on-chronic liver failure (ACLF). The Masterclass was held and recorded as the Keynote Lecture of the 2nd A-TANGO General Assembly (GA) Meeting in Barcelona, Spain, on 11 May 2022.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 945096. This video reflects only the presenter's view and the European Commission is not responsible for any use that may be made of the information it contains.

Production: Tassilo Steinmann and Dr. Nina Donner
Subtitles: Nicolas Lupke
[ Ссылка ]

© 2022 A-TANGO

свернуть